BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22145958)

  • 21. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
    Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
    N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant expression profile of miR-32, miR-98 and miR-374 in chronic lymphocytic leukemia.
    Rahimi Z; Ghorbani Z; Motamed H; Jalilian N
    Leuk Res; 2021 Dec; 111():106691. PubMed ID: 34455196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
    Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
    Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel, mitochondrial, internal tRNA-derived RNA fragment possesses clinical utility as a molecular prognostic biomarker in chronic lymphocytic leukemia.
    Karousi P; Adamopoulos PG; Papageorgiou SG; Pappa V; Scorilas A; Kontos CK
    Clin Biochem; 2020 Nov; 85():20-26. PubMed ID: 32745483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
    Asslaber D; Piñón JD; Seyfried I; Desch P; Stöcher M; Tinhofer I; Egle A; Merkel O; Greil R
    Blood; 2010 May; 115(21):4191-7. PubMed ID: 20089965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia.
    Chen L; Li J; Zheng W; Zhang Y; Wu Y; Li L; Qian S; Xu W
    Leuk Lymphoma; 2007 Sep; 48(9):1785-92. PubMed ID: 17786715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of immunoglobulin heavy and light chain gene expression in chronic lymphocytic leukemia and related disorders.
    Nakahashi H; Tsukamoto N; Hashimoto Y; Koiso H; Yokohama A; Saitoh T; Uchiumi H; Handa H; Murakami H; Nojima Y; Karasawa M
    Cancer Sci; 2009 Apr; 100(4):671-7. PubMed ID: 19220298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.
    Li S; Moffett HF; Lu J; Werner L; Zhang H; Ritz J; Neuberg D; Wucherpfennig KW; Brown JR; Novina CD
    PLoS One; 2011 Mar; 6(3):e16956. PubMed ID: 21408091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD5- B-cell lymphoproliferative disorders presenting in blood and bone marrow. A clinicopathologic study of 40 patients.
    Shapiro JL; Miller ML; Pohlman B; Mascha E; Fishleder AJ
    Am J Clin Pathol; 1999 Apr; 111(4):477-87. PubMed ID: 10191767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.
    Bomben R; Gobessi S; Dal Bo M; Volinia S; Marconi D; Tissino E; Benedetti D; Zucchetto A; Rossi D; Gaidano G; Del Poeta G; Laurenti L; Efremov DG; Gattei V
    Leukemia; 2012 Jul; 26(7):1584-93. PubMed ID: 22343732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
    Xu M; Fan L; Miao KR; Liu P; Xu W; Li JY
    Med Oncol; 2012 Sep; 29(3):2102-10. PubMed ID: 21881978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
    Dal Bo M; D'Agaro T; Gobessi S; Zucchetto A; Dereani S; Rossi D; Zaja F; Pozzato G; Di Raimondo F; Gaidano G; Laurenti L; Del Poeta G; Efremov DG; Gattei V; Bomben R
    Oncotarget; 2015 Aug; 6(22):19102-17. PubMed ID: 26036258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
    Cerna K; Oppelt J; Chochola V; Musilova K; Seda V; Pavlasova G; Radova L; Arigoni M; Calogero RA; Benes V; Trbusek M; Brychtova Y; Doubek M; Mayer J; Pospisilova S; Mraz M
    Leukemia; 2019 Feb; 33(2):403-414. PubMed ID: 30111844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells.
    Ocaña E; Delgado-Pérez L; Campos-Caro A; Muñóz J; Paz A; Franco R; Brieva JA
    Haematologica; 2007 Mar; 92(3):349-56. PubMed ID: 17339184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.
    Ferrajoli A; Shanafelt TD; Ivan C; Shimizu M; Rabe KG; Nouraee N; Ikuo M; Ghosh AK; Lerner S; Rassenti LZ; Xiao L; Hu J; Reuben JM; Calin S; You MJ; Manning JT; Wierda WG; Estrov Z; O'Brien S; Kipps TJ; Keating MJ; Kay NE; Calin GA
    Blood; 2013 Sep; 122(11):1891-9. PubMed ID: 23821659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features.
    Bomben R; Dal-Bo M; Benedetti D; Capello D; Forconi F; Marconi D; Bertoni F; Maffei R; Laurenti L; Rossi D; Del Principe MI; Luciano F; Sozzi E; Cattarossi I; Zucchetto A; Rossi FM; Bulian P; Zucca E; Nicoloso MS; Degan M; Marasca R; Efremov DG; Del Poeta G; Gaidano G; Gattei V
    Clin Cancer Res; 2010 Jan; 16(2):620-8. PubMed ID: 20068100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
    Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
    Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia.
    Sulda ML; Kuss BJ; Hall RK; Bailey S; Macardle PJ
    Intern Med J; 2012 Feb; 42(2):137-46. PubMed ID: 20561095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
    Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
    Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
    Zhu DX; Zhu W; Fang C; Fan L; Zou ZJ; Wang YH; Liu P; Hong M; Miao KR; Liu P; Xu W; Li JY
    Carcinogenesis; 2012 Jul; 33(7):1294-301. PubMed ID: 22610076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.